Health
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day will be both in-person and available to view via webcast.","length":513,"tagName":"p"},{"type":"text","content":"In-Person Information","length":21,"tagName":"p"},{"type":"text","content":"Convene Conference Center530 Fifth AvenueNew York, NY 10036","length":61,"tagName":"p"},{"type":"text","content":"Advance registration is required for in-person attendance. Please contact Aytu's Investor Relations at [email protected] to register.","length":143,"tagName":"p"},{"type":"text","content":"Webcast Information","length":19,"tagName":"p"},{"type":"text","content":"The event will be webcast and accessible live and archived on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations. The event can also be accessed directly at https://app.webinar.net/Qo7DrDvVzq8.","length":260,"tagName":"p"},{"type":"text","content":"Agenda","length":6,"tagName":"p"},{"type":"text","content":"The Investor Day will primarily focus on EXXUA™ (gepirone) extended-release tablets ("EXXUA"), the first and only 5HT1a agonist approved by the United States Food and Drug Administration for the treatment of major depressive disorder ("MDD") which was launched last month.","length":292,"tagName":"p"},{"type":"text","content":"The event will include presentations from Key Opinion Leaders ("KOLs") in the field of psychiatry and Aytu's senior management team regarding the EXXUA opportunity, and will include live Q&A sessions.","length":218,"tagName":"p"},{"type":"text","content":"KOLs scheduled to present include:","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Stephen M. Stahl, MD, PhD, DSc (Hon) will review the 5-HT1A receptor and its clinical importance in major depressive disorder.","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Anita Clayton, MD will disc...